financetom
Business
financetom
/
Business
/
WiseTech Global's board to examine payments to CEO's former partner
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
WiseTech Global's board to examine payments to CEO's former partner
Oct 20, 2024 5:20 PM

(Reuters) -WiseTech Global ( WTCHF ) said on Monday it was reviewing a "full range of matters" concerning its CEO after media reports made allegations about his personal life including payments to a past sexual partner, sending its shares slumping 18%.

The Australian Financial Review and other media outlets reported that a woman who had a sexual relationship with the billionaire chief made a raft of claims against Richard White in late 2020, including allegations that he had engaged in inappropriate behaviour.

Shares of the Australian technology firm dived as much as 18.3% to A$100 and were on track for their worst trading session since late August, 2023.

White, WiseTech's billionaire founder and major shareholder, could not immediately be reached for a comment while WiseTech did not immediately respond.

The reports said White, 69, had approached numerous female entrepreneurs through text messages and social media with offers of professional support that could shift into crude or suggestive language.

The growing media attention on White's private life, with media reports continuing to emerge, has now begun to impact the firm's reputation with its shares falling over 11% since the beginning of the month.

WiseTech said it was seeking further information and taking external advice.

"It is conscious of the potential impacts on the company and will carefully evaluate all relevant factors in its assessment," the tech major said.

White has also continued to sell down his stake in the tech company. In the latest sell-off, White sold 351,038 shares at an average price of A$131.22 apiece between Oct. 11 and Oct. 17, according to a notice filed on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved